NCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
Clinical Trials
31 trialsNCT06550895 2026-04-14
MonumenTAL-8
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04108195 2026-04-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04634552 2026-04-13
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05050097 2026-04-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05552222 2026-04-13
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06285318 2026-04-13
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06500884 2026-04-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06577025 2026-04-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT07032714 2026-04-13
MAGENTA
Massachusetts General Hospital
Phase 1 Recruiting
NCT06353022 2026-03-17
IFm2022-01
Nantes University Hospital
Phase 2 Active not recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06348108 2026-03-13
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT06066346 2026-03-04
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05972135 2026-02-23
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT06100237 2026-02-23
REVIVE
University of Miami
Phase 2 Recruiting
NCT04586426 2026-01-16
RedirecTT-1
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT07093554 2026-01-05
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Recruiting
NCT05695508 2025-12-24
HD10/DSMMXX
University of Heidelberg Medical Center
Phase 2 Recruiting
NCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT04773522 2025-10-01
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT06572605 2025-09-19
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
Phase 1/2 Recruiting
NCT06993675 2025-08-29
ROTATE
Yale University
Phase 2 Recruiting
NCT06461988 2025-08-24
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University
Phase 2 Recruiting
NCT06855121 2025-03-03
NIMMS
St. Olavs Hospital
Recruiting
NCT06505369 2024-07-17
TALTEC
North Estonia Medical Centre
Phase 2 Recruiting